Selenia sales boost Hologic's fiscal year-end revenues

The installation of 27 Selenia full-field digital mammography systems helped Hologic Inc. close FY03, ending Sept. 27, on an upswing.

 The Bedford, Mass., company reached revenues of $204 million in FY03, compared with $190.2 million in FY02. Net income rose to $2.9 million, compared with $179,000 in the previous fiscal year.

 As of Sept. 27, Hologic's backlog for orders of Selenia had increased to 57 systems. Total backlog for all products increased to more than $40 million.

 Hologic Chairman and CEO Jack Cumming described FY03 as "challenging, especially with the transition to selling and servicing our mammography product line on a direct basis in the United States and the worldwide launch of our Selenia full field digital mammography platform."

 Mammography continued to contribute the greatest share to Hologic's revenues. In the fourth quarter, mammography revenues increased 14 percent from the fourth quarter of FY02 to $23.1 million, while osteoporosis assessment revenues accounted for the second-largest product segment with revenues of $18.2 million, a 15 percent gain over the year-ago quarter.

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.